Prospective Observational Real-Life Study (STRATEGE) Shows the Efficacy of Treat-to-Target Strategy and Methotrexate Monotherapy Optimization in Patients with Established Rheumatoid Arthritis

被引：0
|
作者：
Flipo, Rene-Marc [1 ]
Gaujoux-Viala, Cecile [2 ,3 ]
Hudry, Christophe [4 ,5 ]
Zinovieva, Elena [6 ]
Leutenegger, Eric [7 ]
Herman-Demars, Helene [6 ]
机构：
[1] Lille Univ Hosp Roger Salengro, Rheumatol Dept, Lille, France
[2] Univ Hosp Nimes, Rheumatol Dept, Nimes, France
[3] Montpellier Univ, EA2415, Nimes, France
[4] Cochin Hosp, Rheumatol, Paris, France
[5] Rheumatol Inst, F-75008 Paris, France
[6] Nord Pharma, Dept Med, Paris, France
[7] GECEM, Montrouge, France
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
645
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy
    Takeuchi, Tsutomu
    Tanaka, Yoshiya
    Sugiyama, Naonobu
    Iikuni, Noriko
    Soma, Koshika
    Shi, Harry
    Mysler, Eduardo
    Moots, Robert J.
    Smolen, Josef
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [42] EFFICACY OF TOFACITINIB MONOTHERAPY, TOFACITINIB WITH METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE IN PATIENTS WITH EARLY (≤2 YEARS) VS ESTABLISHED (>2 YEARS) RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STRATEGY
    Takeuchi, Tsutomu
    Tanaka, Yoshiya
    Sugiyama, Naonobu
    Iikuni, Noriko
    Soma, Koshika
    Shi, Harry
    Mysler, Eduardo
    Moots, Robert J.
    Smolen, Josef S.
    Fleischmann, Roy
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 373 - 374
  • [43] Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study
    Vassilopoulos, D.
    Delicha, E. M.
    Settas, L.
    Andrianakos, A.
    Aslanidis, S.
    Boura, P.
    Katsounaros, M.
    Athanassiou, P.
    Tempos, K.
    Skarantavos, G.
    Antoniadis, C.
    Papazoglou, S.
    Sakkas, L.
    Galanopoulou, V.
    Skopouli, F.
    Boki, K.
    Daoussis, D.
    Vritzali, E.
    Sfikakis, P. P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (05) : 893 - 900
  • [44] Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study
    Vittecoq, Olivier
    Desouches, Sandra
    Kozyreff, Marie
    Nicolau, Julia
    Pouplin, Sophie
    Rottenberg, Pascal
    Sens, Nicolas
    Lequerre, Thierry
    Avenel, Gilles
    BMJ OPEN, 2019, 9 (12):
  • [45] Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study
    Sandstrom, Tia
    Rantalaiho, Vappu
    Yli-Kerttula, Timo
    Kautiainen, Hannu
    Malmi, Timo
    Karjalainen, Anna
    Uusitalo, Tea
    Julkunen, Heikki
    Kaipiainen-Seppanen, Oili
    Paimela, Leena
    Puolakka, Kari
    Uutela, Toini
    Mottonen, Timo
    Hannonen, Pekka
    Leirisalo-Repo, Marjatta
    Laasonen, Leena
    Kauppi, Markku
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (08) : 1160 - 1164
  • [46] Impact of one-year treatment with biotechnological drugs on work ability in patients with rheumatoid arthritis in Italy: a prospective real-life study
    Manara, M.
    Caporali, R.
    Lomater, C.
    Gorla, R.
    Fusaro, E.
    Sarzi-Puttini, P.
    Stobbione, P.
    Capri, S.
    Sinigaglia, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 39 (02) : 263 - 268
  • [47] Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy
    ten Klooster, Peter M.
    Voshaar, Martijn A. H. Oude
    Fakhouri, Walid
    de la Torre, Inmaculada
    Nicolay, Claudia
    van de Laar, Mart A. F. J.
    CLINICAL RHEUMATOLOGY, 2019, 38 (10) : 2727 - 2736
  • [48] Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy
    Peter M. ten Klooster
    Martijn A. H. Oude Voshaar
    Walid Fakhouri
    Inmaculada de la Torre
    Claudia Nicolay
    Mart A. F. J. van de Laar
    Clinical Rheumatology, 2019, 38 : 2727 - 2736
  • [49] Treat-to-Target in Rheumatoid Arthritis: What Level of Treatment Response Is Necessary By 3 Months in Order to Achieve the Treatment Target By 6 Months? Results from the Real Life NOR-DMARD Study
    Norvang, Vibeke
    Olsen, Inge C.
    Sexton, Joseph
    Kristianslund, Eirik K.
    Uhlig, Till
    Kvien, Tore
    Aletaha, Daniel
    Smolen, Josef S.
    Haavardsholm, Espen A.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [50] TREAT-TO-TARGET STRATEGY OF >8.000 PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: DOES SMOKING AFFECT ACHIEVEMENT OF REMISSION ON METHOTREXATE AND TIME TO START OF FIRST BIOLOGIC? RESULTS FROM THE NATIONWIDE DANISH DANBIO REGISTRY
    Glintborg, B.
    Hendricks, O.
    Colic, A.
    Lindegaard, H. M.
    Ahmed, R.
    Loft, A. G.
    Kollerup, G.
    Andersen, M.
    Grydehoj, J.
    Raun, J.
    Thorgrimsen, T.
    Mortensen, K.
    Uhrenholt, L.
    Jensen, D.
    Ruge, I.
    Kalisz, M.
    Danebod, K.
    Lomborg, N.
    Krogh, N. Steen
    Hetland, M. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 997 - 998
12345